Zacks Research Has Strong Estimate for Omnicell Q3 Earnings

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Stock analysts at Zacks Research lifted their Q3 2025 earnings per share (EPS) estimates for shares of Omnicell in a research report issued to clients and investors on Tuesday, July 15th. Zacks Research analyst R. Department now forecasts that the company will post earnings of ($0.04) per share for the quarter, up from their previous forecast of ($0.05). The consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell's Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.07 EPS, FY2026 earnings at $0.45 EPS, Q1 2027 earnings at ($0.01) EPS and FY2027 earnings at $0.86 EPS.

Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. lowered their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. Wells Fargo & Company reiterated an "overweight" rating and issued a $37.00 price target (up from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Benchmark reduced their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 12th. Finally, Piper Sandler reissued an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $44.83.

Omnicell Price Performance

Shares of Omnicell stock traded down $0.03 on Friday, reaching $27.94. 23,048 shares of the stock were exchanged, compared to its average volume of 559,247. The firm's 50 day moving average is $29.08 and its 200-day moving average is $34.30. The firm has a market cap of $1.31 billion, a PE ratio of 60.73, a P/E/G ratio of 8.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.38. Omnicell has a one year low of $22.66 and a one year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. The company had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.03 earnings per share.

Hedge Funds Weigh In On Omnicell

Several large investors have recently made changes to their positions in the business. Lazard Asset Management LLC lifted its holdings in shares of Omnicell by 81.6% during the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after purchasing an additional 737,536 shares in the last quarter. Toronto Dominion Bank purchased a new stake in Omnicell during the 4th quarter valued at $30,637,000. Dimensional Fund Advisors LP boosted its stake in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after buying an additional 394,820 shares during the last quarter. Oberweis Asset Management Inc. purchased a new position in shares of Omnicell in the 4th quarter worth $14,834,000. Finally, Pacer Advisors Inc. bought a new position in Omnicell in the first quarter valued at about $10,542,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.